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Bence Jones proteins are excreted by patients with multiple myeloma or Walden- 
strSm macroglobulinemia. They have been shown to correspond to the light chains of 
the pathological serum immunoglobulin of these patients (1-2) whenever it is present. 
Patients with multiple myeloma and no detectable pathological serum immunoglobulin 
often excrete Bence Jones protein. 
Two distinct  immunological types  of light  chains  and  Bence Jones proteins  are 
recognized: K and L (3).  Sequence studies have shown that proteins of the same type 
share an identical COOH-terminal half of the sequence, except for single  amino acid 
interchanges, which are the expression of genetic polymorphism (see reference 3 for 
other references). Variability in the NH~-terminal half of the sequence has been ob- 
served by several investigators (4); so far no two identical Bence Jones proteins have 
been found in man. The NH~-terminal half of the sequence of the light chain has thus 
been  designated  variable, whereas  the  COOI-I-terminal  half  has  been  designated 
invariable. 
Gel filtration analysis of the urinary protein of some patients with multiple mye- 
loma has  shown the presence of proteins  of molecular weight smaller  than  that  of 
Bence Jones  proteins  (5-10).  These  proteins  are  structurally  and  immunologically 
related  to the Bence Jones protein from the same patient  (5-10). They have been 
designated "Bence Jones protein fragments" and will be referred to as "fragments." 
Fragments of both K- and L-type proteins have been observed. The relationship  of 
these fragments with the corresponding Bence Jones protein has been investigated by 
means of physicochemical and immunological studies, peptide mapping, amino acid 
analysis, and sequence studies (5-11). Physicochemical studies have shown that these 
proteins have a molecular weight approximately half of that of Bence Jones proteins 
(5--6, 9-10). Immunological studies have shown the presence in fragments of antigenic 
determinants  of the  variable  half of Bence Jones proteins  (8-11);  some fragments 
might have invariable antigenic determinants (8). 
Peptide  maps and amino acid analysis  of fragments have  shown that  these  cor- 
respond with the variable half of the amino acid sequence of the corresponding Benee 
Jones protein (7,  10). Sequence studies have provided evidence that some fragments 
have exactly the same length and sequence as the variable haft, whereas other frag- 
ments appear to be three amino acids longer than the variable half of the corresponding 
Bence Jones protein (10). 
* This investigation has been supported by EURATOM-C.N.R.-C.N.E.N.  Contract No. 
012-61-12 BIAI. 
517 518  ORIGIN  OF  BENCE  JONES  PROTEIN  FRAGMENT 
There has been considerable interest in the study of fragments in view of the pos- 
sible role of these proteins as biosynthetic units in the assembly of immunoglobulin 
chains. The invariable half of each type of chain is under the control of a pair of alleles 
(3); the invariable half is found associated with different variable halves. The simplest 
hypothesis  to  explain  this  puzzling phenomenon  is  to  suppose  that  variable and 
invariable halves are synthesized separately under the direction of distinct structural 
genes. Fusion of the peptide chains after their biosynthesis is completed would then 
occur. The discovery of fragments corresponding to the variable half seemed thus to 
provide some support for this model. 
Pnlse-labeling  experiments on the biosynthesis of the light chains by mouse myeloma 
cells (12)  and of heavy chains by mouse myeloma cells (13)  and rabbit lymphnode 
cells (14)  have shown one point of initiation only for these proteins. It seems thus 
likely that the pepfide chains of immunoglobulins are synthesized in one sequence. 
Therefore, it seems unlikely that the Bence Jones protein fragments represent bio- 
synthetic units. 
It seems, however, important to study the formation of the "fragments" in 
order to explain their peculiar structure. We want to report experiments deal- 
ing with  the  catabolic origin  of  the  "fragments."  Labeled Bence  Jones  pro- 
teins have been injected into patients with multiple myeloma and the appear- 
ance in their urine of labeled "fragments" has been studied. These experiments 
have  shown  that  "fragments"  may  originate  from  a  specific breakdown  of 
Bence  Jones  proteins.  Incubation  of  these proteins with  serum  or urine  has 
shown that this breakdown does not occur in either serum or urine of patients 
with multiple myeloma. It seems possible that some Bence Jones proteins are 
enzymatically degraded  to  "fragments"  during renal excretion.  Other  Bence 
Jones  proteins  are not  degraded in  the  same  way and  thus  no  "fragments" 
originate from their catabolism. 
Materials and Methods 
Bence  Jones  Proteins  and Fragments.--Urinary  proteins have  been  obtained from  two 
patients with multiple myeloma hospitalized at the Division of Hematology, Ospedali Riuniti, 
Naples, Italy. Both patients (No. 27 and No. 98) were in the same age group  (55-60 yr old), 
of the same sex (f), showed no detectable pathological serum immunoglobulin,  and excreted 
large amounts (2-10g/day) of an L-type Bence Jones protein. Patient 27 excreted, in addition 
to the Bence Jones  protein, a fragment in high quantity. The proteins were isolated from 
urine by ammonium sulphate precipitation and gel filtration on Sephadex G-100, using 0.1 
NaC1, 0.02 ~r Tris(hydroxymethyl)aminomethane buffer pH 8.6 as ehiant  (15). The Bence 
Jones protein 27 was further purified by column chromatography on DEAE-Sephadex A-50, 
using a gradient in molarity of Tris buffer pH 8.0 from 0.01 to 0.1 ~ for eiution. 
Labeling of Proteins.--lO--20 mg of protein were incubated for 30 min with 250-500/zc  of 
carrier-free  1251 in the presence  of chloramine-T  according  to Bocci  (16). The protein was 
purified free of unreacted 1251 by gel filtration on a 1.5 cm X 20 cm column of Sephadex G-25, 
using 0.1 ~ NaC1, 0.02 M Tris buffer pH 8.6 as eluant. Under these conditions, no more than 
0.5-1 atom of 125I per molecule was introduced, as determined from the specific activity of the 
protein obtained. Less than 2% of the isotopic label was removed by precipitation of the pro- 
tein with 5% trichloroacetic  acid. Sterile solutions of labeled protein were obtained by filtra- 
tion through Millipore filters of eluates. D.  CIOLI  AND  C.  BAGLIONI  519 
Administration of Labded Proteins.--Patients were given 0.5 ml of Lugol's solution twice a 
day 2 days before the injection of labeled protein and 4 days afterwards. 10 ml of sterile 
solution of Bence Jones protein containing 5-10 mg of protein and approximately 100 #c of 
1~5I were injected intravenously. 
Analysis of Labded Urinary Protein.--Urine was collected after injection of labeled Bence 
Jones protein every 3 or 6 hr into sterile bottles. The bottles were stored immediately in the 
cold and the protein precipitated with ammonium sulphate within the next day. The protein 
precipitated was dialyzed against distilled water and  then lyophili~.ed. 100 mg of protein 
were then aminoethylated and separated by gel filtration on Sephadex G-100 as previously 
described (17). Carrier protein was added before aminoethylation, when necessary. The einate 
of the Sephadex G-100 column was analyzed for OD 280 and for radioactivity. 1-2 ml were 
evaporated to dryness for counting in a low-background or in a gas-flow liquid scintillation 
counter. In one experiment, duplicate samples were precipitated with 5% trichloroacetic acid 
(TCA), filtered on  Millipore filters, and  counted in a  low-background, gas-flow counter. 
Identical results were obtained with samples dried directly and counted. 
Peptide maps of amionethylated Bence Jones proteins and fragments were prepared as 
previously described (17). Peptide maps of 12SI-labeled proteins were examined by radioautog- 
raphy by exposure to Kodak Regulix X-2 films. 
RESULTS 
Analysis  of  Urinary  Proteins.--The  gel  filtration  analysis  of  the  urinary 
protein of patient 27 showed the presence of one minor and two major peaks 
(Fig.  1 a). The minor peak was eluted with the breakthrough volume in vari- 
able yield and was  thought  to consist  of contaminating albumin  and  aggre- 
gated material. Peak 1 was shown to contain Bence Jones protein; when the 
protein  of  this  peak  was  reduced,  aminoethylated,  and  reseparated  by  gel 
filtration, one major peak only was observed (Fig. 1 b).  Peak 2  was shown  to 
contain a  "fragment" which corresponded to the sequence of the variable part 
of the Bence Jones protein 27 (10). Peak 2 also gave one peak in gel filtration 
analysis after reduction and aminoethylation. 
Peaks I  and 2 were used for labeling experiments. Peak 1 in one experiment 
was purified further by column chromatography on DEAE-Sephadex A-50 as 
described under Materials and Methods. 
Patient 27 was followed over a  period of 15 months.  Gel filtration analysis 
of her  urinary protein was repeated  every few weeks.  During  this period of 
time  the  presence  of  Bence  Jones  protein  and  "fragment"  was  constantly 
observed. These proteins appeared to be excreted in a  rather constant ratio, 
the  "fragment" representing  approximately 30-40%  of  the  urinary  protein. 
In the first few samples of urinary protein, the "fragment" appeared in larger 
amount.  This was found  to be caused by a  loss of the  Bence Jones protein, 
which precipitated in part during the dialysis against distilled water and was 
removed  before  lyophilization.  In  later  experiments,  the  urine  was  directly 
lyophilized and the protein then separated by gel filtration. No loss of protein 
was  noticed  by this  procedure.  The  precipitation  of the  protein  during  the 
dialysis was caused by a  reduced solubility at acid pH. Almost all the Bence 
Jones protein could be precipitated by lowering the pH to 5 with acetic acid. 520  ORIGIN  OF  BENCE  JONES  PROTEIN  FRAGMENT 
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The  "fragment"  remained  quantitatively  in  solution  at  this  pH.  For  this 
reason all the preparative gel filtration chromatographies were carried out at 
pH 8.6 to insure maximum solubility of the Bence Jones protein. 
Three or four months after patient 27 came under our observation, intensive 
cortisone therapy was initiated by the physician in charge of this case.  The 
amount of Bence Jones protein and "fragment" excreted decreased consider- 
ably in the course of this therapy, but interestingly enough, even when present 
in  trace  amounts,  the Bence Jones protein  and  "fragment"  were present in 
approximately the same relative ratio as before cortisone therapy. This therapy 
was discontinued and the patient excreted increasing  amounts of urinary pro- 
tein, until her death a year later, caused by bronchopneumonia. 
The gel filtration  analysis of the urinary protein of patient 98 showed the 
presence  of one peak of protein  only. This  protein was studied by peptide 
mapping and was identified with an L-type Bence Jones protein. The reduced 
and aminoethylated protein 98 gave one peak only in gel filtration analysis. 
Excretion  of  Labeled  Bence  Jones  Protein  and  "Fragment".--The  Bence 
Jones protein and  "fragment"  of patient  27 were trace-labeled with x~sI and 
injected intravenously into the same patient.  Urine was collected at 6 hr in- 
tervals for 24 hr and the urinary protein analyzed by gel filtration after reduc- 
tion  and  aminoethylation.  The  results  of this  analysis are shown in  Figs.  2 
and 3. 
Two  controls  were  run  by mixing  the  l~SI-labeled proteins  with  urinary 
protein and separating it by gel filtration. This control analysis showed that the 
labeled  Bence  Jones  protein  was  free  from  significant  contamination  with 
"fragment",  (Fig.  2  a),  whereas the  "fragment"  was slightly  contaminated 
with Bence Jones protein  (Fig.  2 b). Two minor peaks preceded the peak of 
Bence Jones protein in the gel filtration analysis of reduced and aminoethylated 
urinary protein of patient 27. The first minor peak, which was present in vari- 
able yield, contained aggregated Bence Jones protein and possibly "fragment," 
in addition to contaminating  albumin.  The second minor peak was analyzed 
by peptide mapping and showed a pattern of peptides identical to that of the 
Bence Jones protein 27. It was thus thought that this peak consisted of Bence 
Jones protein dimers which were either incompletely split by the reduction in 
8 ~  urea or possibly of aggregated reduced Bence Jones protein monomers, 
which were not dissociated in the eluant used (1 N acetic acid). 
Labeled "fragment"  was injected into patient  27  and  the urinary protein 
analyzed by gel filtration  (Fig.  2, c and d). Maximal excretion in the urine of 
the labeled "fragment" was observed in the 6 hr following  administration  of 
the labeled protein.  Almost all  the 1~5I activity was recovered in  the "frag- 
ment" peak, whereas a small  amount of 125I activity was eluted in the break- 
through peak. It was thus concluded that the injected "fragment" was readily 
excreted as such and was not utilized in any way for the biosynthesis of the 
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Labeled Bence Jones protein 27 was injected into patient 27 and the urinary 
protein analyzed by gel filtration  (Fig.  3). Maximal excretion of labeled pro- 
tein was observed in the first 6 hr of urine collection,  with a steady decrease 
henceforth.  The  125I label  appeared  predominantly  associated  with  Bence 
Jones protein in the first 6 hr urine;  however,  already at this time a noticeable 
amount  of 1~5I activity appeared associated with  "fragment"  (Fig.  3  a)  and 
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FzG. 2. Gel filtration analysis of z2~I-labeled Bence Jones protein 27 and fragment, and of 
urinary protein after administration of 131I-labeled fragment to patient 27. To the labeled 
Bence Jones protein and fragment, 100 mg of carder urinary protein were added before reduc- 
tion and aminoethylation. (a). Labeled Bence Jones 27;  (b), labeled fragment; (c), urinary 
protein of patient 27 collected  in the first  6 hr after administration of fragment; and (d), 
urinary protein collected between 12 and 18 hr. Solid line, OD 280; dotted line, cpm/ml. 
possibly with  other  protein  of smaller  molecular  weight.  A  shoulder  in  the 
profile of the 1~5I activity of the Bence Jones protein peak was observed in the 
gel filtration analysis; this shoulder,  which could not be investigated further, 
may possibly be caused by incompletely degraded  Bence Jones protein.  In 
the 6-12 hr urine,  the 1351 activity associated with fragment is approximately 
1/~ of that of the Bence Jones protein (Fig. 3 b); in the 12-18 hr urine,  Bence 
Jones  protein  and  "fragment"  have  approximately  the  same  activity  (Fig. D.  CIOLI  AND  C.  BAGLIONI  523 
3 c), whereas in the 18-24 hr urine, most of the 12~I activity excreted is asso- 
ciated with "fragment" (Fig. 3 d). 
It seems thus likely that the Bence Jones protein which is excreted rapidly 
is not degraded, whereas Bence Jones protein which remains in the patient 
for a longer period of time is degraded to "fragment." The chemical identity 
of the labeled "fragment" with the naturally occurring fragment could not be 
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Fro. 3. Gel filtration analysis of urinary protein of patient 27  after administration of 
z~I-labeled Bence Jones protein 27. (a) to (d) show the analysis  of the 0-6, 6-12, 12-18, and 
18-24 hr urinary protein, respectively.  Solid  line, OD 280; dotted line, cpm/ml. 
established in these  experiments. It seems likely that the z25I-labeled protein 
eluted with the carrier "fragment" peak was either  identical or very similar 
to natural "fragment" since the profile of the 1~5I activity corresponded exactly 
to that of the OD 280  (Fig. 3). 
In a  subsequent experiment, a  different Bence Jones protein (No. 98)  was 
injected into patient 27  to establish whether the ability to degrade a  Bence 
Jones protein to "fragment" was characteristic of certain patients with mye- 
loma. The results of this experiment are shown in Fig. 4. 
In  a  control gel filtration analysis, x25I-labeled protein 98  was mixed with 524  ORIGIN  OF  BENCE  JONES  PROTEIN  FRAGMENT 
urinary protein of patient 27 (Fig. 4 a). The peak of 125I activity corresponded 
with the Bence Jones protein peak; a  small minor peak was  observed which 
was eluted in a position intermediate between that of the Bence Jones protein 
and that of the "fragment." No corresponding peak of OD 280 was observed 
in the elution profile of protein 98 and the nature of this peak remained un- 
known. 
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FIG. 4. Gel filtration analysis of the urinary protein of patient 27 after administration of 
125I-1abeled Bence Jones protein 98. (a), Control analysis of labded protein 98 mixed with 
carrier urinary protein of patient 27; (b) to (d), analysis of the 0-3, 7-11, and 20-25 hr urinary 
protein of patient 27, respectively.  Solid line, OD 280; dotted line, cpm/ml. 
Again, maximal excretion of the labeled Bence Jones protein was observed 
in the first 3 hr, and the amount of labeled protein excreted decreased steadily 
in the urine collected at following times. The gel filtration analysis of urinary 
protein obtained from the 0-3,  7-11,  and 20-25  hr periods is shown in Fig. 
4 b, c, and d, respectively. The labeled protein was eluted in one major peak D.  CIOLI  AND  C.  BAGLIONI  525 
only, which corresponded exactly to  the Bence Jones protein peak;  a  small 
amount of labeled protein was eluted with the breakthrough peak. The small 
peak present in the control analysis disappeared instead from the elution pro- 
file. 
It seemed thus evident that Bence Jones No. 98 was not degraded to "frag- 
ment" by patient 27 who was able to degrade her own Bence Jones protein to 
"fragment." This was observed in spite of extensive degradation of the labeled 
Bence Jones protein, which occurred in the patient. The recovery of injected 
protein 98  in the urine of patient 27  was carefully estimated by measuring 
the amount of labeled protein recovered in the 25 hr urine following adminis- 
tration. Only 14%  of the label injected was recovered in the 25  hr urine as 
TCA-precipitable 125I activity. Degradation of the injected protein was shown 
by the recovery of 20 % of the label as non-TCA precipitable 125I activity. It 
seems thus likely that breakdown of protein 98  was taking place in patient 
27, but that the products of this breakdown were either free amino acids or 
small peptides, which were not precipitable with ammonium sulphate or were 
dialyzed away in the preparation of urinary protein. 
Patient 98 was no longer available to study the catabolism of labeled pro- 
tein  27  after intravenous administration. This  experiment was  thus  carried 
out in four other patients, three with multiple myeloma and one with Walden- 
strum macroglobulinemia. All these patients excreted large amounts of Bence 
Jones proteins, three of K  type and one of L type. The results of these experi- 
ments were identical in all cases.  Protein 27 was excreted for the major part 
apparently unchanged in the 6 hr following administration. Even in the 6 hr 
urine, however, there is a  detectable amount of fragment present. At subse- 
quent times there is an increasing amount of "fragment" present. 
The results of one such experiment are  presented in Fig.  5.  Bence Jones 
protein  27  repurified by  column  chromatography on DEAE-Sephadex  was 
used  in  this  experiment.  After labeling with l~sI, this  protein  was  purified 
again by gel filtration on Sephadex G-100 to remove the unreacted isotope and 
any possible  trace  of  "fragment." The  control  chromatography  (Fig.  5  a) 
showed indeed no  trace  of  contamination with  "fragment."  10  mg  of  l~sI- 
labeled Bence Jones No.  27  were injected into patient 136, who  excreted  a 
type K  Bence Jones protein. Cold "fragment" was added as a marker to the 
urinary protein of patient 136 in this and in the other gel filtration analysis. 
In the analysis of the 0-6,  12-18,  and 24-30  hr urine, an increasing amount 
of "fragment" was found to be present (Fig. 5 b, c, and d, respectively), whereas 
a  decreasing amount of labeled Bence Jones protein was observed. The abso- 
lute amount of 1~5I activity associated with "fragment" increased in the 24-- 
30 hr urine in respect to the 12-18 hr urine. In the gel filtration analysis of the 
24 hr urine, a  noticeable amount of labeled protein was eluted in an incom- 
pletely resolved peak preceding the peak of Bence Jones protein and in the 526  ORIGIN 0]~ BENCE  ]ONES PROTEIN  FRAGMENT 
breakthrough  peak (Fig.  5  d).  A  similar pattern  of elution  was  observed in 
experiments in which Bence Jones protein 27 was incubated for several hours 
at 37°C  (see below) and was thought to be caused by aggregation of this pro- 
tein, which might have occurred during storage. 
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FIG. 5. Gel filtration analysis of the urinary protein of patient  136 after administration of 
125I-labeled Bence Jones protein 27. To 80 mg of the urinary protein of patient 136, 20 mg of 
tmlabeled fragment of protein Bence Jones No. 27 were added before reduction and amino- 
ethylation.  (a). Control analysis of urinary protein of patient  136 mixed with 125I-labeled 
Bence Jones protein 27; (b) to (d), analysis of the 0-6, 12-18, and 24-30 hr urinary protein 
of patient 136, respectively. Solid line, OD 280; dotted line, cpm/ml. 
In these experiments,  the relative ratio of Bence Jones protein and  "frag- 
ment" excreted did not reach that observed in the experiment in which pro- 
tein 27 was injected into patient 27.  In the 18-24 hr urine of this experiment, 
almost exclusively labeled  "fragment" was excreted by patient  27.  It seems 
thus possible that the breakdown of Bence Jones protein 27  to "fragment" is 
somewhat facilitated in patient 27. 
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Analysis  of  the  125I-Labeled Urinary  "Fragment".--Since  breakdown  to 
"fragment"  of the 125I-labeled protein  27  injected into  patient  136 was ob- 
served,  it  seemed  interesting  to  estabfish  whether  the  labeled  "fragment" 
isolated from the urine of this patient contained the variable half of the amino 
acid sequence of protein 27 or both the variable and the invariable half.  It 
has been rather puzzling  that  only the variable half of several Bence Jones 
proteins  has  so far  been observed in  fragments  that  have been studied by 
peptide mapping  and  amino  acid  analysis  (10).  For  this  reason,  the  "frag- 
ment" isolated from the urine of patient 136 after administration of mI-labeled 
protein 27 was analyzed by peptide mapping and radioantography. 
The  l*5I-labeled Bence Jones protein  27  was injected into  patient  136  as 
described in the preceding paragraph  and the 6-18 hr urine used for the iso- 
lation  of labeled "fragment."  This was obtained free of contamination  with 
Bence Jones protein by preparative gel filtration of reduced and aminoethyl- 
ated urinary protein. The fractions containing Bence Jones protein and "frag- 
ment" were pooled and lyophilized.  The protein was then digested with trypsin 
and  analyzed by peptide mapping  and radioautography as described in Ma- 
terials and Methods. 
In a control experiment, ~25I-labeled Bence Jones protein 27 and "fragment" 
were digested with trypsin and analyzed by peptide mapping and radioautogra- 
phy. The radioautography showed that the a25I label was localized to tyrosine- 
containing  peptides.  When  the peptide map  of the labeled  "fragment"  ex- 
creted by patient 136 was analyzed by radioautography, peptides of the vari- 
able half only were found labeled.  This indicated that the variable half only 
of protein 27 was excreted by patient  136, whereas it provided no indication 
as to the fate of the invariable half. 
Incubation of Bence Jones Protein with Serum or Urine.--To establish whether 
Bence Jones protein 27 was degraded to "fragment"  in the serum or in the 
urine of this patient, ~25I-labeled protein 27 was incubated with serum or urine. 
Urine was obtained from patient 27 and either used directly or filtered through 
Millipore filters  to insure  sterility.  In  these experiments,  2-3 mg of labeled 
Bence Jones protein 27 and  100 mg of carrier urinary protein of patient  27 
were added to 4 ml of urine and incubated for 24 hr at 37°C. As a control,  the 
same mixture was incubated with 4 ml of saline buffer with 0.02 ~ Tris buffer 
pH 7.6. The reduced and aminoethylated protein was analyzed by gel filtra- 
tion after the incubation. The elution patterns of the protein incubated with 
saline  (Fig.  6  a)  was found to be indistinguishable  from that  of protein in- 
cubated with urine  (Fig.  6 b) or sterile urine.  A  considerable  amount of the 
labeled protein  was eluted in  the breakthrough  peak  and  in  a  peak eluted 
between the breakthrough peak and the Bence Jones protein peak. This pattern 
of elution is characteristic of protein which has undergone aggregation and is 
incompletely reduced or dissociated, as it has been pointed out previously. In 
a similar  experiment, 5 mg of l~5I-labeled Bence Jones protein 27 and 100 mg 528  ORIGIN OF  BENCE 5ONES PROTEIN FRAG/~ENT 
of urinary protein of patient 27  were incubated with 0.5  ml of freshly drawn 
serum of patient 27 for 24 hr at 37°C.  The result of the gel filtration analysis 
of  this  incubation  mixture  is  shown  in  Fig.  6  c.  Formation  of  "fragment" 
during this incubation was not observed. 
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Fro. 6. Gel filtration analysis of r~SI-labeled  Bence Jones protein 27 incubated with serum 
or urine of patient 27. (a). Control analysis of labeled protein 27 incubated with saline; (b) 
and (c), analysis of labeled protein 27 incubated with urine or serum, respectively. Conditions 
of the incubation and addition of carrier urinary protein as described in the text. Solid line, 
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DISCUSSION 
We have shown that a  Bence Jones protein "fragment" corresponding to 
the variable half of the amino acid sequence of this protein may originate from 
its degradation. Labeled "fragment" was excreted by the  patient who  orig- 
inally had "fragment" present in urine and by an unrelated patient, upon ad- 
ministration of labeled Bence  Jones  protein.  "Fragment" was formed only 
when the Bence Jones protein of the patient who showed "fragment" in urine 
was administered, whereas it was not formed when a  different Bence Jones 
protein was administered. 
Since the "fragment" was formed both in the patient who had "fragment" 
in urine  and in other patients who showed no "fragment," the capacity to 
degrade a given Bence Jones protein to "fragment" is related to some charac- 
teristic of the structure of some Bence Jones proteins, rather than to a differ- 
ent catabolism of these proteins in different patients. It seems possible that 
the patient who excreted "fragment" in large amount degraded the labeled 
Bence Jones protein to "fragment" more efficiently than other patients. The 
rate  of catabolism of Bence Jones protein may vary considerably from one 
patient to another because of different conditions of renal function (18). 
The  possibility that  the finding of labeled "fragment" in urine  could be 
explained  by  contamination of  the  Bence  Jones  protein  administered with 
trace amounts of "fragment" and its selective excretion was eliminated by the 
following considerations. The amount of labeled fragment excreted could not 
be explained by this contamination, since more 1~5I activity was found asso- 
ciated with the excreted "fragment" than that possibly associated with the 
traces of "fragment" contaminating the Bence Jones protein preparation. In 
one experiment, contamination with "fragment" of the Bence Jones protein 
injected  was  carefully excluded  by  additional  purification  of  this  protein. 
Moreover,  the labeled "fragment" injected appeared  to be excreted rapidly 
and  in high yield shortly after administration, whereas labeled  "fragment" 
was excreted in increasing amount with time after administration of the labeled 
Bence Jones protein. 
Incubation of labeled Bence Jones protein 27 with urine or serum failed to 
show an appreciable breakdown of this protein in 24 hr at 37°C. These experi- 
ments suggest that the breakdown of this protein does not occur either in the 
serum or the urine of the patient. It is, however, possible that in these experi- 
ments optimal conditions for an enzymatic breakdown of the protein were not 
provided. The most likely explanation for these findings is that a fraction of 
the Bence Jones protein which is not excreted undegraded after administra- 
tion becomes in some way more susceptible to proteolytic degradation in the 
kidney. It seems possible that part of the Bence Jones protein 27 becomes less 
soluble at some stage during renal excretion because of pH or ionic conditions, 
and that this fraction is then degraded by proteolytic enzymes. 
The reduced solubility at acid pH was found to be peculiar of protein 27, 530  ORIGIN  OF  BENCE  JONES  PROTEIN  FRAGMENT 
whereas other Bence Jones proteins which were excreted together with "frag- 
ment" showed high solubility at acid pH's (D. Cioli, unpublished results). It 
is remarkable, however, that  the "fragment" of protein 27 is the  "fragment" 
which was present in higher  amount among 100 Bence Jones proteins  studied 
(19). 
The peculiar structure of the "fragments" studied is particularly puzzling. 
This structure  might  be explained  if proteolytic degradation  of Bence Jones 
proteins  occurs predominantly in  the invariable  half  of their  amino  acid se- 
quence. The invariable half is then degraded extensively. 
This hypothesis is in agreement with the fact that we have been unable to 
recover any portion  of the invariable half in urine.  The variable half might 
be  more  resistant  to  proteolytic  degradation  by  endopeptidases,  whereas 
exopepfidases (carboxypepfidases) may digest  amino  acid  residues  from  the 
COOH-terminal end of a Bence Jones protein "fragment." It is possible that 
the  exopeptidase digestion is  arrested  in  a  region  where  the  tridimensional 
configuration of the protein prevents further attack. Alternatively, the region 
of a light chain which joins the variable and invariable halves might be more 
susceptible to  proteolytic attack  than  other  regions,  similarly  to  the  hinge 
region of the heavy chain (see reference  3 for other references).  One can then 
suppose that the invariable half is either less soluble  and/or more susceptible 
to enzymatic degradation,  whereas the variable half is more readily excreted 
undegraded. 
These hypotheses are in accordance with the finding that two K-type "frag- 
ments" correspond exactly to the sequence of the variable half,  whereas two 
L-type "fragments" are three amino acids longer  than the variable half (10). 
The "fragment" of Bence Jones protein 27 is probably a 9:1 mixture of a pro- 
tein corresponding  exactly to the variable half and of a protein three amino 
acid longer (10). Whereas all the other "fragments" studied had a basic amino 
acid,  either  arginine  or lysine,  at their  COOH-end,  the major component of 
fragment 27 has COOH-terminal glycine. 
The present data do not show whether all  the "fragment" originates from 
the catabolism of Bence Jones protein.  It seems still  possible,  although  un- 
likely, that some "fragment" might be synthesized and excreted by myeloma 
cells. 
SUMMARY 
Gel filtration analysis of the urinary proteins of some patients with myeloma 
has shown the presence  of "fragments" of Bence Jones proteins which  corre- 
spond to the variable half of these proteins.  Experiments  have been carried 
out to establish the origin of a "fragment" observed in a patient who excreted 
a large amount of this protein. Labeled homologous  Bence Jones protein has 
been injected into this and other control patients. Excretion of labeled "frag- 
ment"  has  been  observed in  all.  Analysis  by peptide  mapping  and  radio- D.  CIOLI  AND  C.  BAGLIONI  531 
autography of this  labeled  "fragment" isolated  from the  urine  showed  that 
the invariable half of the Bence Jones protein was not excreted; it seemed thus 
likely  that  the  invariable  half  was  metabolized  to  small  peptides  and  free 
amino acids. 
A labeled Bence Jones protein which was excreted without any accompany- 
ing  "fragment"  was injected into the patient who excreted large amounts of 
"fragment."  No  excretion  of labeled  "fragment"  was observed.  It was thus 
concluded that the property of being degraded to "fragment" is characteristic 
of some "fragile" Bence Jones proteins and is not determined by the patient. 
Incubation with serum or urine of the "fragile" Bence Jones protein failed to 
produce any "fragment." "Fragments" of Bence Jones proteins are thus most 
likely formed during excretion of these proteins  through  the kidney and  are 
products of the catabolism of Bence Jones proteins. 
We thank Mr. Guido Sansone for skillful technical assistance. 
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